Evotec SE (EVO)
Evotec SE operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Hamburg, HA, DE. The stock last traded at $2.19, up 4.29% on the session, giving a market capitalisation of $778.0M. On trailing twelve-month figures it carries a trailing P/E of -3.54, a net margin of -26.0%. Its beta of 1.26 implies it has historically moved more than the broad market.
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Evotec SE is most often compared with the following Healthcare names: